Venofer (iron sucrose injection, USP)

MAY 01, 2006

American Regent Inc (Shirley, NY) recently received FDA approval for 2 new indications for Venofer. The product was initially approved for use in the treatment of iron deficiency anemia in hemodialysis (HD) patients receiving an erythropoietin. Venofer now also is indicated for the treatment of iron deficiency anemia in peritoneal dialysis (PD) patients receiving an erythropoietin and in nondialysis chronic kidney disease (CKD) patients receiving or not receiving an erythropoietin. The product can be administered via an intravenous push (100-mg [HD] and 200-mg [CKD] doses) or by infusion (300- and 400-mg doses [PD]) depending on the indication. Venofer is available in 100-mg/5-mL single-dose vials. For more information, visit www.venofer.com, or call 800-645-1706.




SHARE THIS SHARE THIS
0
 

The Oncology Care Pharmacist in Health-System Pharmacy 
According to the National Cancer Institute, almost 40% of men and women will be given a diagnosis of some form of cancer in their lifetime.


 

Pharmacy Times Strategic Alliance
 

Conference Coverage
News from the year's biggest meetings


Pharmacist Education
Clinical features with downloadable PDFs


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.